Overview - The trend of public funds increasing their allocation to the Beijing Stock Exchange (BSE) continues, with active equity public funds significantly entering the market. As of H1 2025, the market value allocated by public funds to the BSE reached 22.383 billion yuan, with an allocation ratio of 0.37%, up by 0.15 percentage points quarter-on-quarter. The allocation coefficient reached 0.59, an increase of 0.07. Public funds have continuously increased their allocation to the BSE for three and a half consecutive half-years since H1 2024 [10][12]. Active Equity - Active equity public funds have significantly increased their allocation to the BSE. As of H1 2025, the total market value held by active equity funds in the BSE reached 11.22 billion yuan, a substantial increase of 116% compared to H2 2024 [29][30]. - The BSE theme products held a market value of 3.9 billion yuan as of H1 2025, up by 54% quarter-on-quarter, primarily due to net value growth and the opening of subscriptions for the "Taikang BSE Selected Two-Year Open Fund" [30][34]. - The average net value growth rate of BSE theme funds was 69.9% from the beginning of 2025 to September 10, 2025, significantly outperforming the BSE 50 index by 14.8% [30][34]. Index Investment - The scale of index investment in the BSE is steadily expanding. As of H1 2025, the market value held by BSE index funds reached 11.08 billion yuan, an increase of 48% quarter-on-quarter. The BSE 50 index fund accounted for 10.5 billion yuan of this, up by 46% [54][55]. - The number of BSE 50 index products has increased, with 28 products established as of now, including two newly established products in Q3 2025 [54][55]. Allocation - The trend of institutionalization in the BSE is accelerating, with a focus on growth sectors. As of H1 2025, the public fund holding ratio for the BSE 50 reached 8.8%, up by 1.8 percentage points quarter-on-quarter. The active equity holding ratio was 3.9%, an increase of 2.0 percentage points [19][20]. - The concentration of active equity public fund allocations has increased, with key stocks like Jinbo Bio, Nacono, and Tongli Co. accounting for about half of the total market value held [40][44].

Summary of Key Points Core Viewpoint - As of September 22, the total margin financing and securities lending balance on the Beijing Stock Exchange reached 7.81 billion yuan, indicating an increase from the previous trading day, with notable activity in specific stocks and sectors [1]. Financing and Margin Activity - The margin financing balance was 7.81 billion yuan, up by 48.08 million yuan, while the securities lending balance was 43.47 million yuan, down by 69,700 yuan [1]. - The stocks with the highest margin financing balances included Better Ray (3.68 billion yuan), Shuguang Digital Innovation (3.65 billion yuan), and Jinbo Biological (3.52 billion yuan) [1]. - The average margin financing balance as a percentage of market capitalization for these stocks was 1.31%, with leading stocks like Juneng Co., Audiwei, and Jiaoda Tifa showing higher ratios of 3.98%, 3.85%, and 3.83% respectively [1]. Net Buying and Selling Trends - On September 22, 150 stocks experienced net margin buying, with 43 stocks having net buying amounts exceeding 1 million yuan [2]. - Shuguang Digital Innovation led with a net buying amount of 9.08 million yuan, followed by Jinbo Biological (8.74 million yuan) and Binhang Technology (7.99 million yuan) [2]. - The stocks with the highest net selling amounts included Kun Gong Technology, Litong Technology, and Kangle Health, with net selling amounts of 9.65 million yuan, 7.40 million yuan, and 6.76 million yuan respectively [1][2]. Industry Performance - The industries with the most stocks receiving net buying over 1 million yuan were machinery equipment (9 stocks), automotive (7 stocks), and electronics (5 stocks) [2]. - The average performance of stocks with net buying over 1 million yuan showed a decline of 1.21%, with notable gainers including Zhixin Electronics (up 12.64%), Shuguang Digital Innovation (up 9.90%), and Kaiter Co. (up 7.05%) [2]. Trading Activity - The weighted average turnover rate for stocks with net buying over 1 million yuan was 4.55%, with the highest turnover rates seen in Shichang Co. (52.17%), Zhixin Electronics (25.83%), and Sanwei Equipment (24.01%) [2]. - The average daily turnover rate for stocks on the Beijing Stock Exchange was 3.71% [2].

Group 1 - The medical beauty sector experienced a decline of 1.81% on September 22, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.20, up 3.56%, and Ai Meike closing at 182.95, down 2.03% [1] Group 2 - The net outflow of main funds in the medical beauty sector was 93.56 million yuan, while retail investors saw a net inflow of 57.63 million yuan [1] - Specific stock fund flows indicated that Ai Meike had a net outflow of 78.89 million yuan, representing a decrease of 13.97% [2] - Huaxi Biological had a net outflow of 17.17 million yuan, down 8.74%, while *ST Meigu saw a net inflow of 2.50 million yuan, up 3.23% [2]

Group 1 - Jinbo Biological has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Biological post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan designated for this project and the remaining 850 million yuan for working capital [2] Group 2 - Yangshengtang's involvement is expected to enhance Jinbo Biological's core competitiveness and innovation capabilities, providing strategic resources for market expansion and sales performance improvement [3] - In addition to Jinbo Biological's developments, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic plans to use the funds raised from the convertible bonds to supplement working capital, thereby alleviating financial pressure and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has received approval from the Beijing Stock Exchange for a targeted stock issuance, with a maximum of 7.1757 million shares to be issued, aiming to raise up to 2 billion yuan [1][2] - The strategic investor for this issuance is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated as follows: 1.15 billion yuan for the development of a humanized collagen FAST database and product development platform, and 850 million yuan for working capital [2] Group 2 - The collaboration with Yangshengtang is expected to enhance Jinbo Bio's core competitiveness and innovation capabilities, as well as improve market expansion and sales performance [3] - In addition to Jinbo Bio's targeted stock issuance, Wantong Hydraulic has also received approval for a targeted convertible bond issuance, with a maximum of 1.5 billion yuan to be raised [4] - Wantong Hydraulic's convertible bonds will be used entirely for working capital, addressing the company's funding needs and enhancing its competitive strength in the hydraulic sector [5]

Group 1 - Jinbo Bio has announced a private placement of shares, which has been accepted by the Beijing Stock Exchange, aiming to raise up to 2 billion yuan by issuing no more than 7.1757 million shares [1][2] - The strategic investor for this placement is Yangshengtang, which will acquire shares at a price of 278.72 yuan per share, resulting in a 6.24% ownership stake in Jinbo Bio post-issuance [2] - The funds raised will be allocated to the development of a humanized collagen FAST database and product development platform, with 1.15 billion yuan dedicated to this project, enhancing the company's competitiveness in various medical fields [2][3] Group 2 - The private placement represents the largest scale of financing through a private placement on the Beijing Stock Exchange this year [2] - Jinbo Bio's collaboration with Yangshengtang is expected to bring advanced technological resources, enhancing core competitiveness and innovation capabilities, as well as improving market channels and brand resources [3] - Meanwhile, Wantong Hydraulic has received approval for a private convertible bond issuance, aiming to raise up to 150 million yuan to support its liquidity needs [4][5]

Core Viewpoint - The recent developments regarding the 2 billion yuan private placement by Zhong Shanshan, the founder of Nongfu Spring, signify a strategic move to enhance the capabilities of Jinbo Biological, positioning it as a leading player in the collagen protein sector in the A-share market [1][2]. Group 1: Company Developments - Jinbo Biological has officially received approval from the Beijing Stock Exchange for its application to issue shares to specific investors, with Yangshengtang being the primary investor [2]. - Yangshengtang, a high-tech enterprise specializing in health products, has a diverse portfolio that includes soft drinks, food, biopharmaceuticals, cosmetics, and health products [2]. - The collaboration with Yangshengtang is expected to empower Jinbo Biological in various aspects such as product development, industrial production, commercialization, market strategy, and management [2][3]. Group 2: Financial Aspects - The total investment from Yangshengtang, through a combination of a directed stock issuance and stock transfer, amounts to 3.403 billion yuan [3]. - The 2 billion yuan private placement is noted as the largest scale of such financing on the Beijing Stock Exchange this year [4]. - Yangshengtang's recent financial data indicates projected revenues of approximately 47.347 billion yuan and a net profit of about 12.128 billion yuan by June 2025, with a debt-to-asset ratio of around 25.08% [4].

证券代码：832982 证券简称：锦波生物 公告编号：2025-160 山西锦波生物医药股份有限公司 关于向特定对象发行股票申请获得北京证券交易所受理的公告 公司本次向特定对象发行股票事项尚需通过北交所审核，并获得中国证券 监督管理委员会（以下简称"中国证监会"）做出同意注册的决定后方可实施， 最终能否通过北交所审核，并获得中国证监会同意注册的决定及其时间尚存在 不确定性。 公司将根据该事项的进展情况及时履行信息披露义务，敬请广大投资者注 意投资风险。 山西锦波生物医药股份有限公司 董事会 2025 年 9 月 19 日 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 9 月 18 日 收到北京证券交易所（以下简称"北交所"）出具的《受理通知书》 （DG2025090001）。北交所经对公司报送的向特定对象发行股票申请文件进行审 核，认为符合《北京证券交易所上市公司证券发行上市审核规则》的相关要求， 并予以受理。 ...

证券简称：锦波生物 证券代码：832982.BJ 山西锦波生物医药股份有限公司 Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. 山西省转型综合改革示范区太原唐槐园区锦波街 18 号 （申报稿） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 签署日期：二零二五年九月 1 2025 年度向特定对象发行股票 募集说明书 保荐机构 声明 本公司及控股股东、实际控制人、全体董事、董事会审计委员会成员、高级管理人员承诺募集 说明书不存在虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律 责任。 本公司负责人和主管会计工作的负责人、会计机构负责人保证募集说明书中财务会计资料真实、 准确、完整。 对本公司发行证券申请予以注册，不表明中国证监会和北京证券交易所对该证券的投资价值或 者投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》的规定，本公司经营与收益的变化，由本公司自行负责，由此变化引致的投资 风险，由投资者自行负责。 1-1-1 | 声明 | 1 | | --- | --- | | 目录 | 2 | | 第一 ...

中信证券股份有限公司 关于 山西锦波生物医药股份有限公司 向特定对象发行股票 之 发行保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二零二五年九月 声 明 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）接受山西锦 波生物医药股份有限公司（以下简称"锦波生物"、"发行人"或"公司"）的 委托，担任其向特定对象发行股票的保荐人。 中信证券股份有限公司及保荐代表人根据《中华人民共和国公司法》（以下 简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《北京证券交易所上市公司证券发行注册管理办法》（以下简称"《注册管理办 法》"）等有关法律、法规和中国证券监督管理委员会（以下简称"中国证监 会"）、北京证券交易所（以下简称"北交所"）的有关规定，诚实守信，勤勉 尽责，严格按照依法制订的业务规则、行业执业规范和道德准则出具发行保荐书， 并保证所出具文件的真实性、准确性和完整性。若因保荐人为发行人本次发行制 作、出具的文件有虚假记载、误导性陈述或者重大遗漏，给投资者造成损失的， 保荐人将依法赔偿投资者损失。 在本发行保荐书中，除上下文另有所指，释 ...